<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Breast Cancer Res</journal-id><journal-title>Breast Cancer Research : BCR</journal-title><issn pub-type="ppub">1465-5411</issn><issn pub-type="epub">1465-542X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">bcr2248</article-id><article-id pub-id-type="pmid">19490591</article-id><article-id pub-id-type="doi">10.1186/bcr2248</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter</subject></subj-group></article-categories><title-group><article-title>Co-incidental increase in gene copy number of <italic>ERBB2 </italic>and <italic>LRIG1 </italic>in breast cancer</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Ljuslinder</surname><given-names>Ingrid</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I4">4</xref><email>ingrid.ljuslinder@onkologi.umu.se</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Golovleva</surname><given-names>Irina</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I4">4</xref><email>irina.golovleva@medbio.umu.se</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Henriksson</surname><given-names>Roger</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I4">4</xref><email>roger.henriksson@onkologi.umu.se</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Grankvist</surname><given-names>Kjell</given-names></name><xref ref-type="aff" rid="I3">3</xref><xref ref-type="aff" rid="I4">4</xref><email>kjell.grankvist@medbio.umu.se</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Malmer</surname><given-names>Beatrice</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I4">4</xref><email>beatrice.malmer@onkologi.umu.se</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Hedman</surname><given-names>H&#x000e5;kan</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I4">4</xref><email>hakan.hedman@onkologi.umu.se</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Radiation Sciences, Oncology, Ume&#x000e5; University Hospital, SE-90187, Ume&#x000e5;, Sweden</aff><aff id="I2"><label>2</label>Department of Medical Biosciences, Medical and Clinical Genetics, SE-90187, Ume&#x000e5;, Sweden</aff><aff id="I3"><label>3</label>Department of Medical Biosciences, Clinical Chemistry, Ume&#x000e5; University, SE-90187, Ume&#x000e5;, Sweden</aff><aff id="I4"><label>4</label>Department of Pathology, Ume&#x000e5; University, SE-90187, Ume&#x000e5;, Sweden</aff><pub-date pub-type="ppub"><year>2009</year></pub-date><pub-date pub-type="epub"><day>12</day><month>5</month><year>2009</year></pub-date><volume>11</volume><issue>3</issue><fpage>403</fpage><lpage>403</lpage><ext-link ext-link-type="uri" xlink:href="http://breast-cancer-research.com/content/11/3/403"/><permissions><copyright-statement>Copyright &#x000a9; 2009 BioMed Central Ltd</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>BioMed Central Ltd</copyright-holder></permissions></article-meta><notes><p>See related research by Ljuslinder <italic>et al.</italic>, <ext-link ext-link-type="uri" xlink:href="http://breast-cancer-research.com/content/7/5/R719"/></p></notes></front><body><sec><title/><p>Using fluorescence <italic>in situ </italic>hybridization (FISH), we previously showed that the <italic>LRIG1 </italic>gene had an increased copy number in 11 of 28 (39%) breast cancer tumours [<xref ref-type="bibr" rid="B1">1</xref>]. The <italic>LRIG1 </italic>gene (leucine-rich repeats and immunoglobulin-like domains 1) at chromosome 3p14 is a proposed tumour suppressor gene that negatively regulates various receptor tyrosine kinases, including the breast cancer proto-oncogene product ERBB2 [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>].</p><p>Recently, however, Miller and colleagues [<xref ref-type="bibr" rid="B4">4</xref>] showed that 10 of 13 (76%) ERBB2<sup>+ </sup>tumours had decreased LRIG1 protein levels compared to normal breast tissue. As their data showed down-regulation at the protein level whereas our data showed an increased copy number at the genomic level, we analysed 45 additional breast tumours by FISH as previously described [<xref ref-type="bibr" rid="B1">1</xref>]. Thus, out of 73 tumours analysed to date, 25 (34%) did indeed have increased <italic>LRIG1 </italic>copy number. To further analyse the relationship between <italic>LRIG1 </italic>and <italic>ERBB2 </italic>at the genomic level, we evaluated the <italic>ERBB2 </italic>gene copy numbers in 18 tumours with increased <italic>LRIG1 </italic>copy number using FISH analysis according to standard procedures. Interestingly, 16 (89%) out of the 18 tumours displayed increased copy number of <italic>ERBB2 </italic>(Figure <xref ref-type="fig" rid="F1">1</xref>). This suggests that the majority of breast cancer tumours with increased copy number of <italic>ERBB2 </italic>simultaneously had increased <italic>LRIG1 </italic>copy number (our data) and decreased LRIG1 protein levels [<xref ref-type="bibr" rid="B4">4</xref>].</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Increased copy number of <italic>LRIG1 </italic>and <italic>ERBB2 </italic>in human breast cancer in the same patient</bold>. Interphase nuclei from a breast cancer tumour were analysed by FISH. <bold>(a) </bold>A specific <italic>LRIG1 </italic>probe (red) showed increased <italic>LRIG1 </italic>copy number (five copies) whereas a specific centromere probe (CEP3) (green) showed normal chromosome 3 copy number (two copies). <bold>(b) </bold>A specific <italic>ERBB2 </italic>probe (red) showed amplification of the <italic>ERBB2 </italic>gene whereas a specific centromere probe (CEP17; green) showed three copies of chromosomes 17.</p></caption><graphic xlink:href="bcr2248-1"/></fig><p>We draw the following major conclusions from these results. First, as previously shown, a significant proportion of breast tumours have an increased <italic>LRIG1 </italic>gene dosage. Second, there is a correlation between increased gene copy numbers of <italic>ERBB2 </italic>and <italic>LRIG1</italic>. Third, based on the Miller protein data, most of the tumours with increased <italic>LRIG1 </italic>gene dosage express reduced levels of the LRIG1 protein. This indicates a negative selection against LRIG1 protein expression, supporting the notion that <italic>LRIG1 </italic>is a tumour suppressor in breast cancer. Although the mechanism behind the down-regulation of LRIG1 protein in breast cancer is not known, it has been reported that increased gene copy numbers in some cases are associated with decreased mRNA expression [<xref ref-type="bibr" rid="B5">5</xref>]. In any case, the high frequency (34%) of tumours with increased <italic>LRIG1 </italic>gene copy number implies a positive selection for tumour cells with this genomic alteration. It remains, however, to be elucidated whether the molecular driver behind the selective advantage associated with this alteration is LRIG1 down-regulation <italic>per se</italic>. Other possibilities include activation of nearby proto-oncogenes or the generation of novel oncogenic fusion genes.</p><p>In summary, the co-incidental increase in copy number of <italic>ERBB2 </italic>and <italic>LRIG1 </italic>in breast cancer is a novel finding, pointing at a functional co-operation between these genetic events, where the biological and clinical importance need to be clarified further.</p></sec><sec><title>Abbreviations</title><p>FISH: fluorescence <italic>in situ </italic>hybridization.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec></body><back><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ljuslinder</surname><given-names>I</given-names></name><name><surname>Malmer</surname><given-names>B</given-names></name><name><surname>Golovleva</surname><given-names>I</given-names></name><name><surname>Thomasson</surname><given-names>M</given-names></name><name><surname>Grankvist</surname><given-names>K</given-names></name><name><surname>Hockenstrom</surname><given-names>T</given-names></name><name><surname>Emdin</surname><given-names>S</given-names></name><name><surname>Jonsson</surname><given-names>Y</given-names></name><name><surname>Hedman</surname><given-names>H</given-names></name><name><surname>Henriksson</surname><given-names>R</given-names></name></person-group><article-title>Increased copy number at 3p14 in breast cancer</article-title><source>Breast Cancer Res</source><year>2005</year><volume>7</volume><fpage>R719</fpage><lpage>727</lpage><pub-id pub-id-type="pmid">16168117</pub-id><pub-id pub-id-type="doi">10.1186/bcr1279</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gur</surname><given-names>G</given-names></name><name><surname>Rubin</surname><given-names>C</given-names></name><name><surname>Katz</surname><given-names>M</given-names></name><name><surname>Amit</surname><given-names>I</given-names></name><name><surname>Citri</surname><given-names>A</given-names></name><name><surname>Nilsson</surname><given-names>J</given-names></name><name><surname>Amariglio</surname><given-names>N</given-names></name><name><surname>Henriksson</surname><given-names>R</given-names></name><name><surname>Rechavi</surname><given-names>G</given-names></name><name><surname>Hedman</surname><given-names>H</given-names></name><name><surname>Wides</surname><given-names>R</given-names></name><name><surname>Yarden</surname><given-names>Y</given-names></name></person-group><article-title>LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation</article-title><source>EMBO J</source><year>2004</year><volume>23</volume><fpage>3270</fpage><lpage>3281</lpage><pub-id pub-id-type="pmid">15282549</pub-id><pub-id pub-id-type="doi">10.1038/sj.emboj.7600342</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laederich</surname><given-names>MB</given-names></name><name><surname>Funes-Duran</surname><given-names>M</given-names></name><name><surname>Yen</surname><given-names>L</given-names></name><name><surname>Ingalla</surname><given-names>E</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Carraway</surname><given-names>KL</given-names><suffix>3rd</suffix></name><name><surname>Sweeney</surname><given-names>C</given-names></name></person-group><article-title>The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>47050</fpage><lpage>47056</lpage><pub-id pub-id-type="pmid">15345710</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M409703200</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>JK</given-names></name><name><surname>Shattuck</surname><given-names>DL</given-names></name><name><surname>Ingalla</surname><given-names>EQ</given-names></name><name><surname>Yen</surname><given-names>L</given-names></name><name><surname>Borowsky</surname><given-names>AD</given-names></name><name><surname>Young</surname><given-names>LJ</given-names></name><name><surname>Cardiff</surname><given-names>RD</given-names></name><name><surname>Carraway</surname><given-names>KL</given-names><suffix>3rd</suffix></name><name><surname>Sweeney</surname><given-names>C</given-names></name></person-group><article-title>Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer</article-title><source>Cancer Res</source><year>2008</year><volume>68</volume><fpage>8286</fpage><lpage>8294</lpage><pub-id pub-id-type="pmid">18922900</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-6316</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stranger</surname><given-names>BE</given-names></name><name><surname>Forrest</surname><given-names>MS</given-names></name><name><surname>Dunning</surname><given-names>M</given-names></name><name><surname>Ingle</surname><given-names>CE</given-names></name><name><surname>Beazley</surname><given-names>C</given-names></name><name><surname>Thorne</surname><given-names>N</given-names></name><name><surname>Redon</surname><given-names>R</given-names></name><name><surname>Bird</surname><given-names>CP</given-names></name><name><surname>de Grassi</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Tyler-Smith</surname><given-names>C</given-names></name><name><surname>Carter</surname><given-names>N</given-names></name><name><surname>Scherer</surname><given-names>SW</given-names></name><name><surname>Tavar&#x000e9;</surname><given-names>S</given-names></name><name><surname>Deloukas</surname><given-names>P</given-names></name><name><surname>Hurles</surname><given-names>ME</given-names></name><name><surname>Dermitzakis</surname><given-names>ET</given-names></name></person-group><article-title>Relative impact of nucleotide and copy number variation on gene expression phenotypes</article-title><source>Science</source><year>2007</year><volume>315</volume><fpage>848</fpage><lpage>853</lpage><pub-id pub-id-type="pmid">17289997</pub-id><pub-id pub-id-type="doi">10.1126/science.1136678</pub-id></citation></ref></ref-list></back></article> 